Follicular Lymphoma
Follicular Lymphoma
The latest news, research, and perspectives in follicular lymphoma (FL).
Patrick DalyFollicular Lymphoma | April 9, 2024
Tumor cells in high-risk follicular lymphoma had enhanced B-cell receptor signaling and distinct follicular growth patterns.
Read More
Melissa BadamoAggressive B-Cell Lymphoma | March 25, 2024
The approval was declined due to the enrollment status of the confirmatory trials.
Patrick DalyFollicular Lymphoma | March 7, 2024
Common adverse reactions to zanubrutinib observed across studies included decreased neutrophil and platelet counts.
Cecilia BrownIndolent B-Cell Lymphoma | March 8, 2024
The multicenter, single-arm phase II trial evaluated axicabtagene ciloleucel in patients with MZL or follicular lymphoma.
Patrick DalyFollicular Lymphoma | March 7, 2024
Axi-cel yielded improved long-term outcomes versus conventional treatments in extended follow-up of the ZUMA-5 trial.
Melissa BadamoFollicular Lymphoma | February 16, 2024
At a median follow-up of 18.1 months, the ORR and CR rates were both 95.7% following liso-cel treatment.
Chadi Nabhan, MD, MBA, FACPThe HemOnc Pulse | February 15, 2024
In episode four of the 2024 season, Dr. Coombs shares updates in CHIP from ASH 2023.
Patrick DalyMantle Cell Lymphoma | April 2, 2024
Liso-cel received regulatory acceptances from the US FDA and the Ministry of Health, Labour and Welfare in Japan for FL.
Leah SherwoodMyeloma | February 2, 2024
The agency's statement follows potential risks identified by the FDA Adverse Event Reporting System.
Patrick DalyFollicular Lymphoma | February 20, 2024
Epcoritamab yielded deep responses with promising response rates in high-risk relapsed or refractory follicular lymphoma.
Melissa BadamoIndolent B-Cell Lymphoma | February 2, 2024
The trial studied a fixed-duration regimen of mosunetuzumab plus lenalidomide in follicular lymphoma.
Melissa BadamoIndolent B-Cell Lymphoma | February 14, 2024
Among 26 response-evaluable patients, the best overall response rate was 96% and the complete response rate was 81%.
Melissa BadamoFollicular Lymphoma | December 13, 2023
The abstract investigators presented data from the phase II TRANSCEND FL trial.
Patrick DalyFollicular Lymphoma | December 14, 2023
Pirtobrutinib showed potential efficacy among patients with relapsed or refractory follicular lymphoma.
Blood Cancer TalksBlood Cancer Talks | December 5, 2023
Dr. Dickinson joins "Blood Cancer Talks" hosts to discuss phase I and II trials on DLBCL, follicular lymphoma, and more.
Patrick DalyFollicular Lymphoma | October 18, 2023
The Committee for Medicinal Products for Human Use of the European Medicines Agency supported approving zanubrutinib for FL.
Melissa BadamoIndolent B-Cell Lymphoma | October 18, 2023
The findings "may contribute to future improved risk assessment and personalized management strategies for patients."
Loretta Nastoupil, MDMeeting News | October 26, 2023
Dr. Nastoupil spoke about how the meeting can help clinicians learn how apply knowledge from the latest research.
Loretta Nastoupil, MDVideo Insights | October 15, 2023
September is Leukemia and Lymphoma Awareness Month, with Lymphoma Awareness Day marked on September 15.
Loretta Nastoupil, MDMeeting News | November 14, 2023
The phase II study evaluated liso-cel in patients with relapsed or refractory follicular lymphoma.
Editorial Board